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A substantial body of evidence accumulated over the past 20 years supports the concept that gC1qR is a major 
pathogen-associated pattern recognition receptor (PRR). This conclusion is based on the fact that, a wide range 
of bacterial and viral ligands are able to exploit gC1qR to either suppress the host’s immune response and thus 
enhance their survival, or to gain access into cells to initiate disease. Of the extensive array of viral ligands that 
have affinity for gC1qR, the HIV-1 envelope glycoprotein gp41, and the core protein of hepatitis C virus (HCV) 
are of major interest as they are known to contribute to the high morbidity and mortality caused by these 
pathogens. While the HCV core protein binds gC1qR and suppresses T cell proliferation resulting in a 
significantly diminished immune response, the gp41 employs gC1qR to induce the surface expression of the NK 
cell ligand, NKp44L, on uninfected CD4+ T cells, thereby rendering them susceptible to autologous destruction 
by NKp44 receptor expressing NK cells. Because of the potential for the design of peptide-based or antibody-
based therapeutic options, the present studies were undertaken to define the gC1qR interaction sites for these 
pathogen-associated molecular ligands. Employing a solid phase microplate-binding assay, we examined the 
binding of each viral ligand to wild type gC1qR and 11 gC1qR deletion mutants. The results obtained from 
these studies have identified two major HCV core protein sites on a domain of gC1qR comprising of residues 
144-148 and 196-202. Domain 196-202 in turn, is located in the last half of the larger gC1qR segment encoded 
by exons IV-VI (residues 159-282), which was proposed previously to contain the site for HCV core protein. 
The major gC1qR site for gp41 on the other hand, was found to be in a highly conserved region encoded by 
exon IV and comprises of residues 174-180. Interestingly, gC1qR residues 174-180 also constitute the cell 
surface-binding site for soluble gC1qR (sgC1qR), which can bind to the cell surface in an autocrine/paracrine 
manner via surface expressed fibrinogen or other membrane molecules. The identification of the sites for these 
viral ligands should therefore provide additional targets for the design of peptide-based or antigen-based 
therapeutic strategies.  
 
1. Introduction 
The receptor for the globular heads of C1q, gC1qR/p33 (also know as p32, HABP-1), is a ubiquitously 
distributed highly acidic (pI 4.15), multicompartmental and multifunctional cellular protein, which modulates a 
plethora of immunological functions including infection, inflammation, autoimmunity, and cancer (1). In 
addition to its known plasma ligands [C1q, high molecular weight kininogen (HK), fibrinogen, thrombin and 
multimeric vitronectin], gC1qR is also able to bind a diverse array of bacterial- (2-4) and viral-associated 
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molecular ligands (5-15) and as such is considered to be a significant pathogen recognition receptor (PRR). The 
core protein of the hepatitis C virus (HCV) and the envelope glycoprotein of the human immunodeficiency 
virus (HIV-1) gp41 are two examples of viral associated molecular ligands that employ gC1qR to induce 
immunosuppression by targeting CD4+ T cells and possibly monocytes. The HCV core protein binds gC1qR on 
T cells and inhibits their proliferation (12) in a manner that is similar to the C1q-induced antiproliferative 
response reported by us earlier (16). Suppression of the host immune response in turn contributes to an 
extremely high rate of viral persistence and severe disease progression (12,17). The HIV-1 transmembrane 
envelope protein gp41 has also been shown to bind to the globular heads of C1q (gC1q) via an external segment 
of the gp41 molecule with residues 601-613 (GIWGCSGKLICTT) of gp160 (inclusive of gp41) having been 
identified as the potential C1q interaction site (18-19).  This interaction in turn has been shown to activate the 
classical pathway of complement (18-19). More recent experiments have also demonstrated that gp41 is able to 
modulate T cell destruction thereby contributing to the persistently low level of T cells seen during the late 
phase of HIV-1 infection (9, 20). An insight into the mechanism of this cell death was recently gained when it 
was shown that the interaction of gp41 and gC1qR plays a central role in this process (9). The 3S motif of HIV-
1 gp41 comprising of residues: PWNASWSNKSLDDIWN–with the highlighted residues being critical–has 
been shown to bind to gC1qR on uninfected CD4+ T cells and to induce surface expression of NKp44L–a 
cellular ligand for the NK receptor, NKp44–thereby rendering them susceptible to autologous NK killing (9).  
Because molecules or peptides that inhibit the interaction between pathogen associated molecular ligands and 
gC1qR can potentially be used as templates for the development of therapeutic interventions, the present studies 
were undertaken to map out and refine the precise gC1qR interaction sites for these important molecules.   
 
2. MATERIALS AND METHODS 
2.1 Chemicals and general reagents 
 The following reagents and chemicals were purchased or obtained from the sources indicated: 
Dulbecco’s PBS (D-PBS) with and without calcium and magnesium (Mediatech Inc, Manassas, VA); 
Dulbecco’s Modified Eagles Medium (DMEM); RPMI 1640, 100x Penicillin/Streptomycin, (GIBCO-
Invitrogen, Grand Island, NY); heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT); human serum 
albumin (HSA) (Immuno-US, Rochester, MI); p-nitrophenyl phosphate (pNPP); alkaline phosphatase (AP)–
conjugated rabbit anti-goat IgG (Pierce, Rockford, IL); C1q (CompTech); and  D-phenylalanyl-L-prolyl-L-
arginine chloromethyl ketone (PPACK)—a specific thrombin inhibitor (Sigma-Adlrich).  
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2.2. Expression of various versions of recombinant gC1qR proteins 
The strategy for the construction of plasmids containing the glutathione-S-transferase (GST)-gC1qR wild type 
(WT), as well as several important deletion (∆) mutants lacking highly charged domains selected on the basis of 
their prominent position in the crystal structure (21) have been described in detail in our earlier publications (1, 
22). In all cases, the final constructs were sequenced to verify sequence integrity. The fusion products were 
purified on glutathione-Sepharose 4B column, then cleaved by thrombin (3.2 µg /ml), and the GST-free gC1qR 
proteins purified on fast protein liquid chromatography (FPLC, Pharmacia) using a Mono-Q ion exchange 
column. After verification by ELISA and visualization by SDS-PAGE (23), the single peak containing the 
gC1qR protein was pooled, concentrated to 1-2 mg/ml, and stored at –800 C in the presence of 50 nM PPACK 
(D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone)—a specific thrombin inhibitor. To estimate the 
organization and integrity of each recombinant protein, gel filtration of purified gC1qR (wild Type, WT) as well 
the deletion mutants was carried out by analytical gel filtration on Superose column (1). With the exception of 
those lacking residues 74-95, 204-218, and 212-223, all of the deletions mutants displayed a properly folded 
trimer as described in detail earlier (1).  
 
2.3. Viral antigens, proteins and antibodies  
Recombinant gp41 as well as mAb to gp-41 was obtained from the NIH AIDS repository Program 
(Germantown, MD).  HCV core protein was purchased from Abcam (Cambridge, MA). Monoclonal and 
polyclonal antibodies to recombinant human gC1qR as well as to gC1qR peptides have been described in 
previous publications and represent part of the anti-gC1qR antibody databank in our laboratory (24). A 17-
residue long synthetic peptide corresponding to the 3S motif of gp41, henceforth called gp41-3S 
(PWNASWSNKSLDDIWNC) with 1 Cys at the C-terminus, as well as affinity purified rabbit anti-gp41-3S 
were made commercially (GenScript, Piscataway, NJ). Monoclonal antibody to E. coli MBP (maltose binding 
protein) was purchased from Sigma.  
  
2.4. Expression and purification of the wild type ghA module and its substitution mutants    
The recombinant globular head protein, ghA, and its respective substitution mutants were expressed as a fusion 
with MBP in E. coli BL21 strain as described earlier (25, 26). Briefly, bacterial cells were grown in 200 ml LB 
medium containing ampicillin (100µg/ml) at 37°C. Once grown to an OD of 0.6, cells were induced with 0.4 
mM IPTG (isopropyl thiogalactoside) for 3 hours and centrifuged (4500 rpm for 15 min). The cell pellet was 
suspended in 25 ml of lysis buffer (20mM Tris pH 8.0, 0.5M NaCl, 1mM EDTA, 0.2% v/v Tween 20, 5% 
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glycerol, 0.1mM PMSF and 0.1g lysozyme) and incubated at 4º C for 1 hour. The cells were then sonicated for 
30 seconds with 2 min gaps for 10 cycles. After centrifugation (13,000 rpm, 15 min) the supernatant was diluted 
5-fold in buffer I (20mM Tris pH 8.0, 100 mM NaCl, 0.2% Tween 20, 1mM EDTA and 5% glycerol) and 
passed through an amylose resin column that had been washed first with 3 bed volumes of buffer I followed by 
buffer II (250 ml of buffer I without Tween 20). The protein was then eluted with 10 mM maltose in 100 ml of 
buffer II. The ghA substitution mutants were generated as described earlier (25-26). 
 
2.5. Cultured cells 
The cell lines, MOLT-4 and U937–representing CD4+ T cell and monocytic cell–were grown in suspension in 
RPMI 1640 containing 10% heat inactivated fetal bovine serum and 100 units/ml penicillin and 100 µg/ml 
streptomycin (GIBCO-Invitrogen, Grand Island NY) and maintained in a humidified air consisting of 5% CO2 
and 95% air as described (1). Prior to each experiment, the viability of cells was verified by Trypan blue 
exclusion and only cultures with ≥95% viability were used for experiments. 
 
2.6. Solid-phase microplate binding assay 
The ability of the various gC1qR proteins to bind to HCV core protein or HIV-1 gp41 was assessed step-wise 
by solid-phase microplate binding assay. The overall strategy taken was to first screen all of the 10 deletion 
mutants and 1 substitution mutant (W233G) for their ability to bind to the target antigen, and once mutants that 
consistently showed diminished binding when compared to the WT gC1qR were identified, they were assessed 
more vigorously in a separate set of experiments. Briefly, microtiter plate wells were coated in duplicate (90 
min, room temp or overnight, 40 C) with 100 µl of either, 2 µg/ml HCV core protein, gp41, or BSA, in 
carbonate buffer, pH 9.6 (15 mM Na2CO3 and 35 mM NaHCO3). The unbound protein was removed; the wells 
washed 2x with TBST (20 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.05% Tween-20), and the unreacted sites 
blocked by incubation (30 min, room temp) with 300 µl of 5% non-fat dry milk or blotto (10 mg/ml casein in 
TBS, pH 8.0). After washing (2x with TBST), the microtiter plate bound HCV or gp41 was incubated (1 h, 
room temp.) with concentrations of biotinylated wild type (WT) gC1qR ranging from 0 to 5 µg/ml. This was 
followed by sequential reaction (1 h each, room temp) with alkaline-phosphatase conjugated streptavidin and 
pNPP. After firmly establishing dose-dependent binding (n=3), experiments were repeated as above to compare 
the binding of either 5 µg/ml biotinylated WT gC1qR or deletion (Δ) mutants followed by sequential reaction 
with alkaline-phosphatase conjugated streptavidin and pNPP as described.  
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2.7. Solid-phase binding of gp-41 or gp41-3S to microplate-fixed cells.  
The ability of gp41 or gp41-3S peptide to bind to gC1qR expressing MOLT-4 or U937 cells was tested using 
microtiter plate fixed cells as described in our earlier publications (1, 24). Briefly, intact cells (2x105 cells/well) 
were first attached (30 min, 22º C) onto poly-L lysine (10 µg/ml in PBS, pH 7.4) coated duplicate ELISA wells. 
Subsequently, the cells were fixed (30 min, 22ºC) by addition of an equal volume of glutaraldehyde (0.5 % 
solution in PBS), and the unreacted sites were quenched with glycine-BSA (100 mM Glycine, 0.1% BSA in 
PBS, pH 7.4). Next, gp41 or gp41-3S ranging from 0-5 µg/ml were added and incubated (60 min, 22º C). Then, 
the bound proteins were detected by sequential interaction with either mAb to gp41 or pAb to gp4-3S followed 
by alkaline-phosphatase conjugated goat anti-mouse or goat ant-rabbit antibody (60 min, 22º C). The reaction 
was further probed by incubation with pNPP and the color developed read spectrophotometrically at 405nm. 
   
2.8. Statistical analysis  
Student t-tests were performed using statistical software (Excel; Microsoft, Redmond, WA, USA). A value of 
p=0.05 was considered to be a significant difference. (n = separate experiments performed in duplicates) 
 
3. Results 
3.1. Identification of the gC1qR site for HCV core protein using gC1qR deletion mutants  
 As shown in Fig 1, the binding of HCV core to gC1qR is fast, reproducible, specific, and dose-dependent. 
Previous studies (12) had suggested that the binding site for HCV core protein resides on a long stretch of 
gC1qR that is encoded by exons IV-VI (residues 159-282). Since this comprises of a large segment of the 
gC1qR molecule, we opted to verify and accurately define the HCV core protein site on gC1qR. To achieve this 
we used a solid-phase microtiter plate-binding assay and tested the interaction of several highly purified gC1qR 
deletion mutants including several deletions from the region encoded by exons IV-VI. The characteristics of the 
10 deletion mutants and the point mutation used in these studies have been described in detail in a previous 
publication (1). When the binding of these gC1qR mutants was assessed using HCV coated wells, two mutants 
lacking residues 144-148 and 196-202 respectively, showed significantly (p≤0.001) reduced interaction with 
HCV core when compared to the WT-gC1qR (Fig 2). Deletion 204-218 also had a significantly diminished 
binding (p≤0.05). However, we think this lack of binding might be due to the fact that deletion of this region is 
known to disrupt the trimerization of the molecule, which is important for the integrity and binding to ligands.  
 
3.2. Identification of the gC1qR site for the HIV-1 gp41  
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Similarly, the interaction between gC1qR and gp41 is also dose-dependent (Fig. 3). Subsequent binding assays 
comparing WT-gC1qR and its deletion mutants showed (Fig. 4) that only gC1qRΔ174-180 (p≤0.01) and to a 
lesser extent W233G (p≤0.05) had a significantly reduced binding to gp41. However, although deletion 74-96 
and 204-218 also showed reduced binding, this is probably due to the disruption of the trimeric integrity, caused 
by deletion of these segments.  
 
3.3. Interaction of gp41 and gp41-3S with isolated and membrane expressed gC1qR.  
The conserved region of gp41 residues 604-609 (NH2-SWSNKS-COOH) has been reported to contain the 
binding site for gC1qR (9). Therefore we generated (GenScript, USA Inc, Piscataway, NJ) a 17-residue 
synthetic peptide, designated gp41-3S (PWNASWSNKSLDDIWNC) with several residues flanking the 
putative gC1qR binding site including an introduction of Cys at the C-terminus to allow conjugation to other 
molecules (e.g. KLH, FITC or biotin). When the ability of this peptide to bind to gC1qR was analyzed, a strong 
and dose-dependent interaction between gC1qR and the peptide over a wide-range of concentrations was 
observed (Fig. 5A) and did not matter which of the reactants was coated onto the microtiter plate (Fig. 5A vs 
B). More importantly, both gp41 (Fig 5C) as well the gp-41-3S peptide (Fig 5D) were able to bind to U937 cell 
surface-expressed gC1qR in a reproducible (n=3) and dose-dependent manner. In addition, gp41-3S peptide was 
able to bind to MOLT-4 cells (n=3), but interestingly this binding was inhibited by two peptides corresponding 
to gC1qR residues 144-162 and 204-218 and not, as expected by peptide 174-180 (Fig 6). Residues 144-162 in 
turn comprise a longer stretch of gC1qR residues within which is contained the 144-148 peptide that, showed 
inhibitory activity for HCV core protein (Fig 2). 
 
3.4.The ghA domain of C1q contains the binding site(s) for both gC1qR and gp41    
 Previous studies using both ligand blot and peptide mapping analyses have shown that gC1qR binds to gC1q 
predominantly via the A chain (ghA residues 155-164) and moderately to ghB and ghC chains. Furthermore it 
was shown that the two adjacent Arg residues at positions 162 and 163 in the ghA chain are critical for this 
binding (27). Indeed ghA mutants in which, the Arg at position 162 was substituted with either Ala (R162A) or 
Glu (R162E) failed to bind gC1qR (Fig. 7) thus confirming earlier results (27). Since the HIV-1 gp41 also binds 
to the A-chain of C1q (18-19, 26), we examined if the two proteins bind to the same or overlapping regions of 
C1q.  Employing several synthetic peptides derived from the A-chain of C1q spanning the collagen region 
(residues 14-26), the globular head region (residues 155-164) as well as a region at the interface between the 
globular and collagen regions (residues 76-92), we compared the binding of gp-41 peptide and gC1qR. The 
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surprising finding as shown in Fig.8 is that, while both gC1qR and gp41 were found to bind strongly (p≤0.05; 
n=3) to the A-chain residues 14-26, and 76-92 only gC1qR was found to bind to the globular head region 
residues 154-164 of C1q as expected. Furthermore, the binding of gC1qR to gp41 peptide coated plates was 
found to be enhanced rather than inhibited when the plates were first pre-incubated with increasing 
concentrations of C1q (Fig. 9), suggesting that either the gC1qR is binding to the gp41 bound C1q itself or to 
both the C1q and gp41 suggesting that the binding sites for gp41 and gC1qR on gC1q may not overlap.  
 
4. DISCUSSION 
There is a growing list of pathogenic microorganisms (1, 24) that target the gC1qR molecule for their 
pathogenic design. Among these are two important pathogens: hepatitis C virus (HCV) and HIV-1, both of 
which suppress or destroy T cells via gC1qR (9,16, 17). Hepatitis C virus is a major cause of chronic hepatitis 
worldwide, and is the leading cause of hepatocellular carcinoma and to date there is no effective treatment (28).  
Similarly, the mortality and morbidity caused by HIV infection is staggering. According to the WHO in 2014 
alone close to 37 million people have been diagnosed with HIV-1 infection and approximately 1.5 million have 
died of AIDS or AIDS-related diseases of which almost 70% are in sub-Saharan Africa. Therefore, 
understanding at the molecular level, the virus-host cell interaction and, in particular, identification of novel 
molecular targets that contribute to the pathogenesis of HIV-1 AIDS, will not only give us insight into how they 
manipulate and escape the onslaught of the innate immune defense mechanism, but may provide us with 
alternative approaches for designing better or adjuvant therapeutic options.  
 Previous studies have shown that the 22 KDa, unglycosylated non-enveloped HCV core protein binds 
gC1qR on CD4+ T cells and induces an anti-proliferative or pro-apoptotic response. Suppression of T cells in 
turn, is postulated to contribute to an extremely high rate of viral persistence and severe disease progression (12, 
17, 28).  Furthermore, gC1qR has been shown to play a role in the pathogenesis of HCV-related cryoglobulin 
vascular damage (29). Mixed cryoglobulinemia (MC) is a lymphoproliferative disorder observed in 10-15% of 
patients with HCV and the non-enveloped HCV core protein is detected in cryoprecipitable immune complexes 
and interacts with gC1qR on cells. More importantly, the levels of circulating gC1qR in chronically infected 
patients with MC is significantly higher than in infected patients without MC, and the circulating gC1qR is 
found predominantly in complex with C1q and HCV core protein. Together these data suggest that gC1qR 
contributes to vascular cryoglobulin-induced damage via activation of the classical pathway of complement 
(29).  Although the binding of HCV core protein has been previously suggested to be in a domain within a long 
stretch of gC1qR comprising of residues 188-259 (17), the precise binding site has not been identified. In this 
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study, we not only confirmed that the interaction site is indeed within the previously suggested region of 
gC1qR, but also mapped more precisely the HCV core protein site(s) to two gC1qR domains comprising of 
residues 144-148 and 196-202. These residues make up the loops in each gC1qR monomer that connect β3 to 
β4 and β5 to β6 (Fig 10), respectively in the structure of the protein (21,22). These prominent loops (which 
cover up much of the doughnut hole of the gC1qR homotrimer, are highly charged and probably form a binding 
“cluster in space” in the native molecule. Interestingly, the gC1qR doughnut hole of which these residues are 
part of also overlaps with the binding site (residues 204-218) for high molecular weight kininogen (22), which 
is recognized by mAb 74.5.2. 
 Similarly, the envelope glycoprotein gp41 of human immunodeficiency virus type 1 (HIV-1) interacts 
with gC1qR on CD4+ T cells. This interaction is considered to enhance the destruction of uninfected T cells by 
activated NK cells thereby contributing to the persistently low level of T cell count seen in the late phase of the 
disease (9). While the gC1qR interaction site on gp41 has been mapped to the 3S motif comprising of gp41  (9), 
the complementary binding site for gp41 on gC1qR has not been identified. In the present study, we have 
identified gC1qR residues 174-180 as a major binding site for HIV-1 gp41. Domain 174-180, which has 
recently been shown to contain the cell surface-binding site for soluble gC1qR, is a highly conserved loop, 
which connects β4 to β5 in the 3D structure of gC1qR (1, 21-22). Previous studies by others have also shown 
that C1q, the natural ligand for gC1qR, binds to gp41 and the binding site was mapped to a domain, which is 
adjacent to the 3S motif of gp41 (18-19). Although the biologic significance still remains to be assessed, it is 
intriguing to find that the binding sites for gC1qR and C1q be localized in the same stretch of the gp41-3S 
domain. Furthermore, both gp41-3S and gC1qR appear to compete for the same binding site(s) on the ghA 
chain of C1q (Fig. 8). The biological implication of a simultaneous binding of gp41 and C1q to gC1qR 
expressing CD4+ T cells or the binding of gp41 to monocytes such as the monocytic cell line U937, which 
express membrane-associated C1q in addition to gC1qR should be intriguing and will be vigorously pursued in 
future studies  
 Viral envelope proteins such as the outer envelope protein gp120 of HIV-1 have been recognized to 
share some structural and functional similarities with C1q (8). These structural similarities had in fact allowed 
us to predict that proteins like gC1qR that are able to interact with C1q may also interact with isolated gp120 or 
even with the whole HIV-1 virus. Previous experiments that were performed to test this hypothesis in fact led to 
the observation that recombinant gC1qR could effectively and dose-dependently inhibit the production of one 
T-lymphotropic (X4) and one macrophage-tropic (R5) strain in human T cell lines (MT-4 and H9) and human 
monocyte-derived macrophage cultures, respectively (8). Interestingly, the extent of this inhibition was 
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enhanced when gC1qR was first incubated with and then removed from the target cell cultures before virus 
infection, compared to that when the cells were infected with gC1qR-HIV mixtures (8). Furthermore, these 
experiments showed that although gC1qR did not bind to a solid-phase recombinant gp120, it showed a strong 
and dose-dependent binding of gC1qR to solid-phase CD4 (8). Since gp120 within the gp120/gp41 complex 
determines viral tropism and the role of gp41 is to mediate fusion between viral and cellular membranes (20), 
gC1qR may prevent the latter process by binding to gp41 within the complex in the early phase of viral 
infection. While these results imply a beneficial role of gC1qR for the host, a darker side to this interaction is 
when gp41, potentially released during infection, interacts with cell surface gC1qR to favor viral survival 
through destruction of CD4+ cells (30-31). Since the great majority of dying cells during the latter phase of 
HIV-1 infection are the uninfected CD4+ T cells, the interaction of gp41 and gC1qR can play a significant role 
in perpetuating the disease process by enhancing the autologous destruction of not only these cells (9, 29-30), 
but also of other cells including malignant ones. The destruction of uninfected T cells is therefore postulated to 
be in part responsible for the persistently low T cell count during viral infection (9, 30-31). The identification of 
gC1qR domain 174-180 as a major binding site for gp41, therefore presents an alternative template for the 
design of either peptide-based or antibody-based therapy that salvages CD4+ T cells from gp41 mediated 
destruction. However, it should also be pointed out that although peptide 174-180 showed significantly reduced 
binding to microtiter plate bound gp41 (Fig 4), it did not block the binding of gp-41S to MOLT-4 cells. Instead 
peptides 144-162 and 204-218 appear to block this binding on intact cells (Fig.6) indicating that the interaction 
of gp41 with cell surface-expressed gC1qR may be different than the binding to isolated gC1qR. Since gC1qR 
is highly expressed on malignant cells, and it has been shown to induce NKp44L expression, it also has the 
potential to serve as a molecular target to induce on tumor cells NKp44L expression resulting in autologous 
NK-cell-mediated tumor cell destruction (9). 
 The present studies also identify three potential gp41 binding sites on the A chain of C1q which more or 
less paralleled that of gC1qR, although gC1qR was not known to bind to the collagen tail of C1q.  Interestingly 
the strongest interaction was seen with the amino terminal peptide 14-26 followed by peptide 76-92, of C1q A 
chain. Peptide 14-26, contains two adjacent arginine residues (AGRPGRRGRPGLK) and has been shown to be 
a promiscuous binding site for several important ligands including CRP (31) DNA  (33), S. Minnesota-derived 
LPS (34), and human serum amyloid protein (SAP) (35). The second peptide 76-92, which is located at the 
interface between the collagen and globular head region of C1q (GIKGTKGSPGNNIKDQPR), is also a 
promiscuous binding site for several non-immunoglobulin molecules including the same proteins that bind to 
peptide 14-26 mentioned above albeit, with much lower affinity (36). Therefore in addition to the globular head 
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region of its A-chain, C1q possesses at least two sites in its collagen-like region, which support classical 
pathway complement activation, and is therefore likely to be exploited by pathogen associated molecular 
ligands and thereby modulate the host immune response.  
 In summary, the present studies have identified three important gC1qR sequences (Fig 10) that may 
have relevance in HCV core binding (residues 144-148 and 196-202) and gp41 binding (residues 174-180). As 
described in detail in our earlier publication (22), all three sequences are part of a highly acidic region of gC1qR 
that are localized in the S-face (Solution Face) of the 3D structure. In fact residues 144-148 and 196-202 form 
part of the highly charged residues [141-146 (PTFDGE) and 191-196 (DEVGQE)] that have high solvent 
mobility and are therefore unlocated in all three chains of the 3D structure (22). Residues 174-180 
(IKNDDGKKA) on the other hand are part of a highly conserved stretch found in many organisms with only 
one or two amino acid substitutions (bold and underlined). These include Trichomonas vaginalis G3 
(IKNDDLKKA) Borrelia valaisiana (IKNDDIKKA), Borrelia burgdorferi B31 (IKNEDGKKV) and 
translation initiation factor (IF-2) in zebra fish (IKNDDGRKA). The fact that this sequence is highly conserved 
across species suggests that it may fulfill highly relevant and possibly multiple biological functions. 
Furthermore, although the sequences identified indicate that they play a role in the respective bindings of HCV 
core and gp41, the exact binding sites may involve other residues, which together could form a “cluster-in-
space” that defines the perimeter of the binding pocket.  However, verification of this postulate could only be 
accomplished by solving the 3D structure of gC1qR in complex with the HCV core protein and gp41, which we 
intend to do in the near future. Regardless, the present information should provide an initial platform for the 
design of more refined peptide-based or antibody-based inhibitors that block interaction of gC1qR with its viral 
ligands: HCV core and HIV-1 gp-41.  
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Legends to Figures 
 
Figure 1.  Dose–dependent binding of gC1qR to HCV core protein. Microtiter plate wells were first coated with 
2 µg/ml HCV core protein (1 h, 37º C).  After washing and blocking with 5% non-fat dry milk, the bound HCV 
core protein was reacted (overnight, 4 º C) with concentrations of biotinylated WT gC1qR ranging from 0-5 
µg/ml followed by sequential reaction with alkaline-phosphatase conjugated streptavidin and pNPP following 
the standard procedure for ELISA. Each data point is a mean ±SD of duplicate experiments and the figure is a 
representative of three such experiments.  
 
Figure 2. Comparative binding of WT gC1qR and gC1qR deletion mutants with HCV core protein.  Preliminary 
microplate binding studies were first performed as above to compare the binding of biotinylated WT gC1qR and 
the 10 deletion and 1 substitution mutants to microtiter plate coated HCV core protein as described in the legend 
to Fig.1. After three such tests, the deletion mutants that showed consistently diminished binding to HCV core 
were selected and further analyzed. Data shown in (A) include data of only the deletion mutants (out of 11 
mutants) that reacted weakly with HCV core protein. The residue numbers indicate the segment of the deleted 
gC1qR region (Δ) and the location in the gC1qR 3D structure of one such deleted region is shown in red (B). 
The significance of data is indicated as: *p ≤ 0.05 and ***p ≤ 0.001. 
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Figure 3.  Binding of gC1qR to the HIV-1 envelope glycoprotein, gp41. ELISA plate wells were first coated 
with 100 µl per well of 2 µg/ml of gp41 (1 h, 37º C).  Following blocking with 5% non-fat dry milk for 1 h, 
wells were washed (3x with TBS-T) and incubated with concentrations of gC1qR (1µg, 0.5 µg and 0.25 µg/ml) 
in TBS, (1 h, 37º C). Bound gC1qR was then detected using mAb 74.5.2 anti-gC1qR (0.5 µg/ml) followed by 
sequential reaction with alkaline phosphatase goat anti-mouse IgG and pNPP. The absorbance of the color 
developed after 30 min was measured spectrophotometrically at 405 nm. Each data bar is a mean ±SD of each 
experiment run in duplicates  (n=3). 
 
Figure 4. Identification of gp41 site on gC1qR using gC1qR deletion mutants. The same strategy as in Fig. 2 
was applied in that the deletion mutants that showed consistently diminished binding to gp41-coated wells were 
selected and compared.  Microtiter plate wells were first coated with 2 µg/ml HIV-gp41 (1 h, 37º C) as 
described in the legend to Fig.3 and after washing and blocking, the bound gp41 was reacted (O/N, 4 º C) with 
2.5 µg/ml of biotinylated WT gC1qR or the selected biotinylated gC1qR deletion (Δ) mutants. The single point 
mutation is indicated as G substitution for W at position 233 (W233G). The position of residues 174-180, which 
showed significantly reduced binding to gp41 (A), is shown in the gC1qR 3D structure (B). The significance of 
the data is indicated as: * p ≤ 0.05 and  **p ≤ 0.01. 
 
Figure 5. Interaction between HIV-1 gp41-3S and gp41 and recombinant gC1qR and cell surface expressed 
gC1qR.  (A) Duplicate wells of a microtiter plate were coated with 100 µl of 2µg/ml gC1qR and incubated (60 
min, 37 º C). After blocking, the bound gC1qR was reacted (1 h, 37º C) with concentrations of synthetic gp41 
3S peptide ranging from 1-5 µg/ml (A) and the bound peptide was detected using an affinity purified rabbit 
anti-gp41 peptide IgG.  In (B) the reaction sequence was reversed in that the wells were first coated with 100 µl 
of 100 µg/ml gp41-3S peptide, then was reacted with increasing concentrations of biotinylated gC1qR (0-
100µg/ml) and the bound gC1qR was detected using alkaline phosphatase conjugated streptavidin. The 
experiments in (C) and (D) are similar except that microtiter plate-fixed cells were used and reacted with either 
various concentrations of purified gp41 (C) or the gp41-3S peptide (D) and the bound protein was detected 
using mAb to gp41 or immunoaffinity purified anti-gp41-3S peptide antibody. Each data point is a mean ±SD 
run in duplicates (n=3). 
 
Figure 6. Inhibition of gp41-3S peptide binding to MOLT-4 cells by gC1qR peptides. First the binding of gp41-
3S peptide to MOLT-4 cells was verified using microtiter plate fixed MOLT-4 cells (A) as described in detail in 
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Material and Methods. The bound gp41-3S peptide was detected using rabbit anti-gp41-3S antibody. Then the 
ability of selected gC1qR peptides (corresponding to the deleted regions) to inhibit the binding of gp41-3S 
peptide to MOLT-4 cells was carried out by preincubation of 100 µl of 5 µg/ml of each peptide with MOLT-4 
cells (O/N, 40 C). Then the unbound gC1qR peptides were removed and the wells further incubated with gp41–
3S peptide (1 h, room temp). After incubation the bound gp41-3S peptide was detected with affinity purified 
anti-gp41-3S peptide, and the reaction developed following the protocol for a standard ELISA (B). For visual 
clarity, the location of one of the inhibitory peptides (aa204-218) within the gC1qR 3D structure is shown in 
(C). The significance of the data is indicated as: **p ≤ 0.01; n=3. 
 
Figure 7: Interaction of ghA mutants with gC1qR.  Microtiter wells were coated with 1.0, 0.5 or 0.25  µg/well 
of gC1qR in carbonate buffer and the plate incubated at 4º C overnight. The next morning, contents were 
discarded and wells were blocked for 2 h with 2% BSA at 37º C. After washing with PBS + 0.05% Tween, 2.5 
µg/well of ghA wild type, R162A, R162E and MBP was added and the plate was incubated 1.5 h, 37º C and 1.5 
h at 4º C. Wells then were washed and anti-MBP (1 g/ml) was added, incubated for 1 h 37º C and the bound 
protein was detected using horseradish peroxidase conjugated IgG. After addition of OPD buffer, the colour 
developed was read at 450 nm. Each data bar is a mean ±SD run in duplicates (n=3). 
 
Figure 8. Localization of the gp-41 binding site on the A-chain of C1q.  Various peptides from selected regions 
of the A-chain of C1q were synthesized and 100 µl of 1 mg/ml of each was coated onto ELISA wells in 
duplicates following the standard ELISA described above.  After blocking, 100µl of either 5µg/ml of gC1qR or 
200µg/ml of gp41-3S were added and incubated overnight at 4º C. After removal of the excess unbound 
reactants and washing, the bound gC1qR and gp41-3S were detected using mAb 74.5.2 or anti-gp41-3S  
antibody respectively, following standard ELISA procedure. The designation QQ (residues 155-164) indicates 
that two Q residues at positions 162 and 163 substituted the two R residues. The significance of binding of 
gp41-3S to C1q peptide 14-16 was (p ≤ 0.05; n=3) whereas to 76-92 was (p ≤ 0.001). 
 
Figure 9.  Effect of preincubation of gp41-3S with C1q on the binding of gC1qR to gp41-3S.  Standard ELISA 
was performed in which microtiter bound gp41-3S peptide (2 µg/ml) was first incubated with increasing 
concentrations of C1q before addition of a concentration of gC1qR that gives optimal binding under similar 
experimental conditions. The bound gC1qR in turn was detected with mAb 74.5.2 and further developed 
following standard ELISA protocol.  Each data point is a mean ±SD run in duplicates (n=3). 
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Figure 10. Location of the gC1qR residues that disrupt trimer formation. All the deletions retained the trimeric 
integrity of the gC1qR molecule with the exception of residues 74-95, 204-218 and 212-223, which did not.  
The location of these residues (shown in red) within the 3D structure as seen from both the S- and M-faces is 
shown on the left panel. Figures (A and B) on the right panel show the secondary structure of a single monomer 
of gC1qR showing that the loops connecting β3 to β4 and β5 to β6 strands occupy a large part of the doughnut 
hole in the homotrimer (A). In (B) the residues comprising the entire monomer are shown for reference. The 
structures in A and B were adapted from ref 21.  
 
